EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

What this study is about

The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.

Who can join (things the study team will check)

✅ You may be able to join if…

• The participant or a legally authorized representative must provide study-specific informed consent prior to study entry.
• The participant must be ≥ 18 years of age.
• ECOG performance status 0 or 1.
• Histologically confirmed invasive carcinoma of the breast.
• Planned neoadjuvant therapy which includes cytotoxic chemotherapy.
• Tumor size ≥ 2.1 cm in greatest diameter.
• Unifocal or multifocal cancer documented to be the same histologic clinical subtype.
• Clinically node positive or if node negative, any one of the following: i. High tumor grade (G3) ii. Ki67 index of 20% or higher iii. High genomic risk (Oncotype DX® (ODX) Breast Recurrence Score of > 25, MammaPrint® High, etc.)
  • TNBC or HER2+ subtype
  • HR+/HER2-negative with at least one of the following:
• Willing and able to comply with the study requirements, which includes the collection of a total of 34 cc (2.5 Tablespoons) of blood for each research blood draw.
• Available residual tissue from diagnostic biopsy from the breast or an involved ipsilateral lymph node for submission to create a bespoke ctDNA assay.

🚫 You may not be able to join if…

• Definitive clinical or radiologic evidence of metastatic disease.
• Initiated neoadjuvant therapy for current breast cancer diagnosis.
• Synchronous diagnosis of another invasive cancer, other than this breast cancer, except for non-melanoma skin cancers.
• Completed all therapy (including endocrine therapy) <5 years ago for any previous invasive solid organ malignancy (with exception of non-melanoma skin cancers) including prior breast cancer. Individuals with a prior history of noninvasive (in situ) carcinomas may participate if they have received definitive treatment.
• Completed all therapy for any previous hematologic malignancy < 5 years ago.
• Multicentric or contralateral invasive breast cancers.
• Known pregnancy at time of enrollment.
• Prior solid organ transplant.
• Prior allogeneic hematopoietic stem cell transplant.

Where this trial is running

• Katmai Oncology Group - Anchorage, Anchorage, Alaska, United States
• Stanford Cancer Institute, Palo Alto, California, United States
• Harbor-UCLA Medical Center - Hematology / Oncology, Torrance, California, United States
• Kaiser Permanente Medical Center, Vallejo, California, United States
• UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, Colorado, United States
• AdventHealth East Altamonte Oncology and Hematology, Altamonte Springs, Florida, United States
• Mount Sinai Medical - Comprehensive Cancer Center, Miami Beach, Florida, United States
• Baptist Cancer Care - Plantation, Plantation, Florida, United States
• St. Joseph's Women's Hospital, Tampa, Florida, United States
• Rush Cancer Center, Chicago, Illinois, United States
• Deaconess Chancellor Center for Oncology, Newburgh, Indiana, United States
• University of Kansas Cancer Center, Westwood, Kansas, United States

+ 46 more sites.

Who to contact

NSABP Department of Site and Study Management Department of Site and Study Management · 1-800-270-3165 · industry.trials@nsabp.org

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06401421.